

Antibiotic Susceptibility of *Escherichia coli* ATCC® BAA-196™

| Antimicrobial | MIC ^a | Interpretation ^b | Antimicrobial | MIC | Interpretation |
|-----------------------------|------------------|-----------------------------|-----------------------------------|-------|----------------|
| Amikacin | 32 | I | Cefuroxime | 8 | S |
| Amoxicillin/Clavulanic Acid | 4 | S | Cefuroxime Axetil | 8 | R |
| Ampicillin | ≥32 | R | Ciprofloxacin | ≤0.25 | S |
| Ampicillin/Sulbactam | ≥32 | R | Ertapenem | ≤0.5 | S |
| Aztreonam | ≥64 | R | Gentamicin | ≥16 | R |
| Cefalotin | 32 | R | Imipenem | ≤0.25 | S |
| Cefazolin | ≤4 | R | Levofloxacin | 0.25 | S |
| Cefepime | ≤1 | R | Meropenem | ≤0.25 | S |
| Cefotaxime | ≤0.25 | S | Moxifloxacin | ≤0.25 | S |
| Cefotetan | ≤4 | S | Nalidixic Acid | ≥32 | R |
| Cefoxitin | 8 | S | Nitrofurantoin | ≤16 | S |
| Cefpodoxime | ≥8 | R | Piperacillin/Tazobactam | ≤4 | S |
| Ceftazidime | 32 | R | Tetracycline | 8 | I |
| Ceftazidime/Avibactam | ≤0.12 | S | Tigecycline | ≤0.5 | S |
| Ceftolozane/Tazobactam | ≤0.25 | S | Tobramycin | ≥16 | R |
| Ceftriaxone | ≤1 | R | Trimethoprim/ Sulfamethoxazole | ≥320 | R |

^a Antibiotic susceptibility was obtained using a Vitek 2 AST-GN69 and AST-XN09 cards.

^b Parameter set: MIC Interpretation Guideline: CLSI M100-S30 (2020)
Therapeutic Interpretation Guideline: Natural Resistance